MBP-B (84-102) DRB1*15:01

Myelin Basic Protein (MBP)

MBP-B (84-102) DRB1*15:01 is a short part of the myelin basic peptide. Myelin basic protein is one of the major protein found in myelin.

MBP-B (84-102) DRB1*15:01

MBP-B (84-102) DRB1*15:01 is used to stimulate immune response and T cell activity. MBP-B (84-102) DRB1*15:01 is also considered as a reference positive control in binding affinity with DRB1*15:01 molecules.


Technical specification

 MBP-B (84-102) DRB1*15:01 Sequence : NPVVHFFKNIVTPRTPPPS
 MBP-B (84-102) DRB1*15:01 MW : 2147,48 g/mol (C101H155N27O25)
 MBP-B (84-102) DRB1*15:01 Purity : > 95%
 MBP-B (84-102) DRB1*15:01 Counter-Ion : TFA Salts (see option TFA removal)
Peptide library synthesis MBP-B (84-102) DRB1*15:01 Delivery format : Freeze dried in propylene 2mL microtubes
peptide solubility guidelines Peptide Solubility Guideline
buy peptide price Bulk peptide quantities available



Product catalog Size Price € HT Price $ HT
SB119-0.5MG 0.5 mg 110 138
SB119-1MG 1 mg 198 248



1- Van der Aa A, Hellings N, Medaer R, Gelin G, Palmers Y, Raus J and Stinissen P. Clin Exp Immunol. 131(1):155-168 (2003)
T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study


Myelin-reactive T cells are considered to play an essential role in the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. We have previously studied the effects of T cell vaccination (TCV), a procedure by which MS patients are immunized with attenuated autologous myelin basic protein (MBP)-reactive T cell clones. Because several myelin antigens are described as potential autoantigens for MS, T cell vaccines incorporating a broad panel of antimyelin reactivities may have therapeutic effects. Previous reports have shown an accumulation of activated T cells recognizing multiple myelin antigens in the cerebrospinal fluid (CSF) of MS patients. We conducted a pilot clinical trial of TCV with activated CD4+ T cells derived from CSF in five MS patients (four RR, one CP) to study safety, feasibility and immune effects of TCV. CSF lymphocytes were cultured in the presence of rIL-2 and depleted for CD8 cells. After 5-8 weeks CSF T cell lines (TCL) were almost pure TCR alpha beta+CD4+ cells of the Th1/Th0 type. The TCL showed reactivity to MBP, MOG and/or PLP as tested by Elispot and had a restricted clonality. Three immunizations with irradiated CSF vaccines (10 million cells) were administered with an interval of 2 months. The vaccinations were tolerated well and no toxicity or adverse effects were reported. The data from this small open-label study cannot be used to support efficacy. However, all patients remained clinically stable or had reduced EDSS with no relapses during or after the treatment. Proliferative responses against the CSF vaccine were observed in 3/5 patients. Anti-ergotypic responses were observed in all patients. Anti-MBP/PLP/MOG reactivities remained low or were reduced in all patients. Based on these encouraging results, we recently initiated a double-blind placebo-controlled trial with 60 MS patients to study the effects of TCV with CSF-derived vaccines in early RR MS patients.

2- Hirasawa M, Hagihara K, Abe K, Ando O and Hirayama N. Int J Mol Sci. 18(4):694 (2017)
In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01


Idiosyncratic ximelagatran-induced hepatotoxicity has been reported to be associated with human leukocyte antigen (HLA)-DRB1*07:01 and ximelagatran has been reported to inhibit the binding of the ligand peptide to HLA-DRB1*07:01 in vitro. In order to predict the possible interaction modes of ximelagatran with HLA-DR molecules, in silico docking simulations were performed. Molecular dynamics (MD) simulations were also performed to predict the effect of ximelagatran on the binding mode of the ligand peptide to HLA-DRB1*07:01. A series of in silico simulations supported the inhibitory effect of ximelagatran on the binding of the ligand peptide to HLA-DRB1*07:01 in vitro. Furthermore, direct interactions of ximelagatran with HLA-DR molecules were evaluated in vitro, which supported the simulated interaction mode of ximelagatran with HLA-DRB1*07:01. These results indicated that ximelagatran directly interacts with the peptide binding groove of HLA-DRB1*07:01 and competes with the ligand peptide for the binding site, which could alter the immune response and lead to the idiosyncratic ximelagatran-induced hepatotoxicity.

3- Rohowsky-Kochan C, Eiman D and Cool S D. J Neurol Sci. 117(1-2):120-9 (1993)
Individual specific bias usage of HLA-DR antigens in the restriction of myelin basic protein-reactive T cell clones


Multiple sclerosis, a demyelinating disease of the human central nervous system occurs in genetically susceptible individuals through a presumably autoimmune mechanism directed against the myelin sheath. The influence of the major histocompatibility locus on T cell recognition of myelin basic protein (MBP), a suspected target autoantigen, was investigated by analyzing MBP-specific T cell clones generated from the peripheral blood of healthy individuals. Inhibition studies using monoclonal antibodies demonstrated that MBP recognition was restricted by HLA-DR antigens. MBP recognition of the majority of T cell clones from each individual was restricted predominantly by one of the DR alleles. Thus, there appears to be a bias in the use of allelic DR restricting elements for MBP responses.

4- Salvat R, Moise L, Bailey-Kellogg C, Griswold K E. J Vis Exp. (85):51308 (2014)
A high throughput MHC II binding assay for quantitative analysis of peptide epitopes


Biochemical assays with recombinant human MHC II molecules can provide rapid, quantitative insights into immunogenic epitope identification, deletion, or design(1,2). Here, a peptide-MHC II binding assay is scaled to 384-well format. The scaled down protocol reduces reagent costs by 75% and is higher throughput than previously described 96-well protocols(1,3-5). Specifically, the experimental design permits robust and reproducible analysis of up to 15 peptides against one MHC II allele per 384-well ELISA plate. Using a single liquid handling robot, this method allows one researcher to analyze approximately ninety test peptides in triplicate over a range of eight concentrations and four MHC II allele types in less than 48 hr. Others working in the fields of protein deimmunization or vaccine design and development may find the protocol to be useful in facilitating their own work. In particular, the step-by-step instructions and the visual format of JoVE should allow other users to quickly and easily establish this methodology in their own labs.